Continuing the Conversation: Starting Treatment: Buprenorphine Induction 101

Date: January 28, 2020, 12-1PM

Featured Speaker: Candy Stockton, MD

Note: Registering here will allow you to attend any of our future sessions. You can cancel your registration at any time.

Description: This one-hour Q & A session with Candy Stockton, MD is a follow up to the January 14th webinar on buprenorphine starts in various treatment settings. It will offer an opportunity to "continue the conversation" with Dr. Stockton and ask specific questions about best practices on starting buprenorphine treatment for opioid use disorder. Attendance at the first event is not required.

Continuing Medical Education and Continuing Education (CME/CE) credit offered at no cost!

For more information, contact Cfrable@mednet.ucla.edu

Shared Medical Appointments for MAT Treatment

Date: February 11, 2020 12-1PM

Featured Speaker: Cheryl Ho, MD

Note: Registering here will allow you to attend any of our future sessions. You can cancel your registration at any time.

Description: This one-hour web training will provide an overview of using shared medical appointments in MAT treatment. Dr. Ho will describe the research behind this approach, the benefits, and practical steps to implement group visits in treatment settings.

Continuing Medical Education and Continuing Education (CME/CE) credit offered at no cost!

For more information, contact Cfrable@mednet.ucla.edu

Starting Treatment: Buprenorphine Induction 101

Featured Speaker: Candy Stockton, MD

Description: This one-hour web training will provide an overview of best practices on how to start buprenorphine treatment for opioid use disorder in a variety of settings, including hospitals, emergency department, and office-based settings. The presenter will also cover safe home induction protocols and other recommendations.

 

Demystifying DEA's Role in MAT Regulation & Implementing a Zero Risk Program

Featured Speaker: Dennis A. Wichern

Description: This one-hour web training will provide an overview of the authority of the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), and Substance Abuse and Mental Health Services Administration (SAMHSA) as it relates to regulating the use of medications in the provision of treatment for opioid use disorders (OUD), along with a review of national studies, risk mitigation strategies, case studies, emerging issues, commonly asked questions, and strategies for preventing a DEA audit. The goal of the training session is to alleviate provider concerns relative to operating a MAT medical practice.

 

Opioids as an Emergency

Featured Speaker: Aimee Moulin, MD

Description: In this one-hour webinar, Aimee Moulin, MD, frames opioid use disorder (OUD) as a medical emergency and highlights the role emergency departments and other health care providers can play in helping patients start treatment for OUD.